Close
Loading...
CONTACT US
:
:
:
Call us at:
:
:
:
Fax:
Email:

TREM1

Products

Loading...

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Background

Triggering receptor expressed on myeloid cells 1 (TREM1) is a plasma membrane integral immune receptor encoded by TREM1 gene, predominantly expressed within myeloid immune cell populations including dendritic cells, macrophages and monocytes, localized exclusively to cell surface lipid bilayers. Distinct from other pattern recognition receptors, TREM1 relies on extracellular ligand-binding domains to drive recognition of pathogen-derived and damage-associated molecular fragments, while simultaneously controlling the delivery of pro-inflammatory stimulatory signals toward intracellular adaptor complexes to amplify innate immune signal cascades. Under resting physiological immune states, basal TREM1 surface expression sustains normal immune cell surveillance without triggering excessive inflammatory activation. Upon pathogen uptake and tissue damage, accumulated stimulatory ligands bind to membrane TREM1, facilitating downstream pro-inflammatory cytokine secretion programs. Unlike broad-spectrum immune receptors with general surveillance roles, TREM1 bears specialized pro-inflammatory amplifying functions that cannot be fully compensated by other myeloid receptors, linking extracellular danger signal recognition directly to inflammatory activation pathways. Loss of functional TREM1 severely blunts myeloid cell-mediated innate immune responses and weakens host anti-bacterial defense capacity, while sustained overactive TREM1 signaling amplifies chronic inflammatory pathology, establishing TREM1 as a core research target for myeloid membrane receptor biology and innate immune regulatory mechanism exploration.

TREM1 executes core ligand-sensing receptor function embedded within cell surface lipid bilayers, utilizing conserved extracellular binding pockets to power recognition of pathogen and damage-related molecular substrates. Conserved extracellular ligand binding regions exclusively recognize microbial and tissue damage fragments, separating its substrate spectrum from other immune receptors distributed on immune cell surfaces. TREM1-mediated ligand sensing bridges extracellular danger signal detection and intracellular inflammatory signal transduction, balancing immune surveillance efficiency and pathogen-triggered inflammatory signal intensity according to external stimulus load. TREM1 participates in extensive physiological processes including myeloid cell danger sensing, innate immune signal amplification and tissue inflammatory response modulation. Deficient TREM1 expression disrupts pathogen pattern recognition and impairs systemic innate immune surveillance. Therefore, TREM1 represents a pivotal research target for myeloid membrane receptor study and anti-inflammatory compound screening.

Fig. 1 TREM1 anti-tumor immune signaling schematic for combined immunotherapy research. (OA Literature)Fig. 1 Targeting TREM1 restrains tumor growth by remodeling suppressive myeloid microenvironment and blocking PI3K/Akt/mTOR cell cycle pathway.1

TREM1 Protein Function: Core Roles in Danger Ligand Recognition and Myeloid Inflammatory Tuning

The biological functions of TREM1 are focused on danger molecule sensing, inflammatory signal amplification and myeloid immune response control:

  • Ligand-Driven Danger Recognition: Captures pathogen and tissue damage molecular substrates on cell exterior.
  • Inflammatory Signal Amplification: Transmits stimulatory intracellular signals to boost myeloid cell inflammatory secretion.
  • Immune Surveillance Maintenance: Sustains low-level pathogen monitoring under steady physiological conditions.
  • Myeloid Immune Modulation: Governs the magnitude of pro-inflammatory cytokine secretion upon pathogen exposure.
  • Disease Relevance: TREM1 loss suppresses anti-pathogen immunity, while hyperactivity drives persistent inflammatory pathology.

TREM1 Protein Product

Creative Biolabs offers high-quality TREM1 proteins through optimized expression systems, including full-length myeloid membrane receptor and isolated extracellular ligand-binding domain variants. These products retain native conformational characteristics and ligand-dependent immune activation biological activity, suitable for membrane receptor interaction assays and inflammatory modulator screening. All TREM1 proteins undergo strict quality control to ensure consistent performance and reliable application across diverse research platforms.

TREM1 Membrane Protein Product

Not finding the membrane protein product you need? Contact us to start your one-stop custom service!

TREM1 Stable Cell Line Product

Creative Biolabs provides custom-engineered TREM1 stable cell lines, including overexpression and blank control models. These cell lines are optimized for myeloid receptor expression profiling and inflammatory signal functional analysis. Each cell line undergoes stringent validation to ensure stable expression profiles and consistent functional performance in diverse experimental contexts.

TREM1 Stable Cell Line Product

Not finding the stable cell line product you need? Contact us to start your one-stop custom service!

TREM1 Recombinant Antibody Product

High-specificity recombinant antibodies targeting TREM1 are developed via advanced antibody engineering technologies, with no cross-reactivity with other TREM family myeloid receptors. These antibodies are validated for plasma membrane subcellular localization detection and myeloid tissue expression profiling, and can be combined with inflammatory signaling detection reagents to analyze complete TREM1 signal complexes in immune cell models.

TREM1 Recombinant Antibody Product

Not finding the recombinant antibody product you need? Contact us to start your one-stop custom service!

Product Features

  • Native Ligand Sensing Activity: Preserves intact extracellular ligand recognition capacity for myeloid inflammatory receptor research.
  • TREM Isoform Specificity: Eliminates non-specific cross-recognition of other TREM family membrane receptors.
  • Innate Immunology Compatibility: Optimized reagent series for myeloid inflammatory signaling and anti-inflammatory screening workflows.
  • Comprehensive Customization Support: Facilitates end-to-end development of customized proteins, antibodies and stable cell lines to address myeloid membrane receptor research demands.

Custom TREM1 Research Services

Beyond catalog products, Creative Biolabs offers specialized custom services for TREM1 research:

  • Custom TREM1 Protein Production: Tailored expression of mutant and tagged TREM1 constructs for ligand-receptor binding interaction analysis.
  • Custom Antibody Development: Generation of TREM1-specific antibodies for plasma membrane immunostaining in myeloid cell populations.
  • Stable Cell Line Engineering: Construction of TREM1-modified cell models for myeloid inflammatory signaling research.
  • Functional Assay Development: Custom design of ligand sensing and inflammatory cytokine secretion detection workflows.

Frequently Asked Questions (FAQ)

  1. What is the primary function of TREM1?

    TREM1 is a myeloid cell surface receptor that recognizes danger-associated ligands to amplify innate inflammatory immune activation.

  2. Why is TREM1 a significant research target?

    TREM1 acts as a critical link between extracellular danger signal detection and myeloid inflammatory response, governing host anti-pathogen and inflammatory immune responses.

  3. Are Creative Biolabs' TREM1 products suitable for clinical use?

    No, all TREM1 products and services are strictly for research use only, not intended for clinical diagnosis or treatment.

  4. What types of TREM1 products does Creative Biolabs offer?

    Offerings include full-length TREM1 membrane receptors, isoform-specific detection antibodies and custom stable cell lines for myeloid inflammatory research.

  5. How are TREM1 proteins validated for activity?

    TREM1 proteins undergo assay-specific quality control and are evaluated for their suitability in binding studies.

Reference
  1. Ajith, Ashwin, et al. "Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti–PD-1 resistance." The Journal of Clinical Investigation 133.21 (2023). Under Open Access license CC BY 4.0, without modification. https://doi.org/10.1172/JCI167951
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2026 Creative Biolabs. | Contact Us
;